Concurrent Endocrine Disorders in Canine Diabetes: Diagnostic and Therapeutic Implications for Clinical Practice

In dogs with diabetes mellitus, persistent hyperglycaemia or wide glycaemic variability despite appropriate insulin therapy frequently indicates the presence of concurrent endocrine disease. Contemporary literature consistently identifies endocrine comorbidities; particularly hyperadrenocorticism, as major contributors to insulin resistance and unstable glycaemic control in diabetic dogs. Rather than reflecting inadequate insulin dosing alone, poor regulation in these patients often arises from complex hormonal interactions that alter glucose metabolism and insulin sensitivity. 

Endocrine Interactions Affecting Glucose Homeostasis 

Canine diabetes mellitus is characterised predominantly by insulin deficiency, but insulin resistance may coexist when counter-regulatory hormones are excessive. Cortisol excess, as seen in hyperadrenocorticism, promotes hepatic gluconeogenesis, reduces peripheral glucose uptake, and antagonises insulin action at the cellular level¹. Tardo’s synthesis of recent endocrinology advances further emphasises that this hormonal environment increases glucose variability rather than producing stable hyperglycaemia alone, complicating interpretation of routine glucose measurements². 

Hypothyroidism and hypoadrenocorticism are less commonly associated with diabetic dysregulation but may influence insulin requirements indirectly through altered metabolism and stress responses^2,3. The literature supports evaluating endocrine balance when glycaemic instability persists despite apparent treatment adherence. 

Diagnostic Considerations in the Diabetic Dog 

Diagnosis of concurrent endocrine disease in diabetic dogs is inherently challenging due to overlapping clinical signs. Polyuria, polydipsia, polyphagia, and abdominal distension are common to both diabetes mellitus and hyperadrenocorticism, potentially delaying targeted investigation^1,2. Evidence-based reviews recommend that suspicion should be heightened when insulin requirements escalate progressively; glycaemic variability increases, or clinical signs persist despite reasonable glucose control¹. 

Tardo highlights that diagnostic testing for hyperadrenocorticism, including ACTH stimulation testing and low-dose dexamethasone suppression testing should be interpreted cautiously in diabetic dogs, as metabolic instability itself may influence endocrine test results². Where possible, partial stabilisation of diabetes prior to endocrine testing is advised to improve diagnostic accuracy. 

Therapeutic Implications of Treating Concurrent Endocrinopathies 

Evidence from open-access reviews indicates that addressing underlying endocrine disease can improve glycaemic stability in diabetic dogs, even though insulin dependence remains lifelong^1,2. Treatment of hyperadrenocorticism has been associated with gradual reductions in insulin resistance, leading to decreased insulin requirements over time rather than immediate normalisation of glucose values¹. 

Tardo emphasises that insulin dose adjustments following initiation of therapy for hyperadrenocorticism should be conservative and guided by monitoring rather than expectation of rapid improvement². This approach reduces the risk of hypoglycaemia as insulin sensitivity evolves. Importantly, none of the referenced studies suggest restoration of endogenous insulin secretion, reinforcing that therapeutic goals should focus on stability rather than remission^1,3. 

Role of Monitoring in Complex Endocrine Cases 

While current evidence does not demonstrate outcome superiority with advanced glucose monitoring in dogs with concurrent endocrine disease, monitoring remains essential for interpretation³. Tardo’s work underscores that serial glucose assessment, whether through structured curves or ambulatory monitoring can help clinicians distinguish persistent insulin resistance from episodic dysregulation related to hormonal fluctuations or treatment transitions². 

Such monitoring supports informed clinical decisions without implying direct therapeutic benefit, aligning with evidence-based practice standards. 

Clinical Takeaways 

Current evidence confirms that concurrent endocrine disorders, particularly hyperadrenocorticism, significantly affect insulin sensitivity and glycaemic stability in diabetic dogs. Poor glycaemic control in these cases often reflects hormonal interference rather than insufficient insulin therapy. Diagnostic evaluation and treatment of underlying endocrinopathies can improve metabolic stability, though diabetes remain irreversible and insulin dependent. 

 References  

1. Behrend EN, Kooistra HS, Nelson R, Reusch CE, Scott-Moncrieff JC. Diagnosis and management of hyperadrenocorticism in dogs: recent advances and clinical implications. Front Vet Sci. 2022;9:889972. 
   Available from: https://www.frontiersin.org/articles/10.3389/fvets.2022.889972 

2. Tardo AM. Advancements in diagnostic, therapeutic, and monitoring options for canine and feline diabetes mellitus, canine hypoadrenocorticism, and canine hypercortisolism. Doctoral thesis. University of Bologna; 2023. 
   Available from: https://amsdottorato.unibo.it/id/eprint/11874/1/Tardo_Antonio%20Maria_Tesi.pdf 

3. Nelson RW, Reusch CE. Animal models of disease: classification and pathophysiology of diabetes in dogs and cats. Front Vet Sci. 2024;11:1284371. 
   Available from: https://www.frontiersin.org/articles/10.3389/fvets.2024.1284371